Rettenbacher Maria A, Hummer Martina, Hofer Alex, Baumgartner Susanne, Ebenbichler Christoph, Edlinger Monika, Kemmler Georg, Lechleitner Monika, Wolfgang Fleischhacker W
Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria.
J Psychopharmacol. 2007 Jun;21(4):400-4. doi: 10.1177/0269881106069467. Epub 2006 Oct 18.
Although second-generation antipsychotics have notable benefits as compared to typical antipsychotics, their use has been associated with metabolic disturbances, such as alterations of glucose homeostasis. It is still being debated whether this is a class effect of second-generation antipsychotics. We conducted a prospective, open study comparing body weight, parameters of insulin resistance in schizophrenia patients treated with either clozapine (n = 10) or amisuLpride ( n = 12). All parameters were assessed monthly over a period of 12 to 16 weeks. Body mass index (BMI), fasting serum insulin levels and the Homeostasis Model Assessment (HOMA) index for insulin resistance increased significantly in patients treated with clozapine. None of these parameters increased significantly in patients treated with amisulpride. This study indicates that treatment with clozapine appears to have a higher risk to lead to metabolic disturbances than amisupride.
尽管与典型抗精神病药物相比，第二代抗精神病药物有显著益处，但其使用与代谢紊乱有关，如葡萄糖稳态改变。第二代抗精神病药物是否存在此类药物类别效应仍存在争议。我们进行了一项前瞻性、开放性研究，比较了接受氯氮平（n = 10）或氨磺必利（n = 12）治疗的精神分裂症患者的体重及胰岛素抵抗参数。在12至16周的时间里，每月评估所有参数。接受氯氮平治疗的患者体重指数（BMI）、空腹血清胰岛素水平及胰岛素抵抗的稳态模型评估（HOMA）指数显著升高。接受氨磺必利治疗的患者这些参数均未显著升高。该研究表明，与氨磺必利相比，氯氮平治疗似乎导致代谢紊乱的风险更高。
